IMGN is moving up nicely, I'm surprised no one here is talking about it.
I believe all the negative from the AdamF article is being dismissed by knowledgeable investors, both individual and Institutional. I suspect Institutions are more into IMGN than ever before, we'll know when they report mid quarter. With just a couple more positive revelations on other drugs, as well as sales of Kadcyla, I expect IMGN will climb back into the $20's. From there, more positive news on Kadcyla sales and expansion of it's label, as well as other drugs advancing, could easily lead to share prices never before seen by IMGN.
It certainly wouldn't hurt if IMGN in another big name Pharma in partnership, but when you look at the list they already have it's not only impressive, but you need to recognize that for each one in the clinic, most partners have at least a few others licensed, or the ability to license more drugs at will.
Gary |
